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Abstract
Sepsis kills nearly 1 million people each year in the United States and sepsis-related
hospitalizations cost approximately $24 billion annually (Paoli, Reynolds, Sinha, Gitlin, &
Crouser, 2018). Current treatment guidelines are limited to targeted antibiotics and
hemodynamic support. While antibiotics are the definitive treatment to eradicate the infectious
pathogen, there are currently no standard-of-care treatments that consistently and successfully
attenuate the damage sustained to the body by its own inflammatory response to infection. Many
different treatments have been trialed and failed to show improved outcomes. Vitamin C, or
ascorbic acid, has long been associated with supporting immune function, and has been studied
in the past in various related capacities. More recently, a study initiated by Dr. Paul Marik has
spurred much discussion and additional research regarding the potential use of ascorbic acid as
an adjunctive treatment for sepsis patients. Research suggests that it may reduce damage by
reducing oxidative stress, regulate the body’s immune response, and facilitating the production
of endogenous vasopressin. Discussion will include the mechanism of action of ascorbic acid in
the body, its potential role, efficacy, and safety in the treatment of sepsis, as well as additional
treatment components. Also discussed is the cost in both dollars and mortality, of waiting to
implement the widespread use of what appears in some studies to be a low-cost, low-risk, highreward treatment.
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Introduction
Sepsis is an ongoing and some say a steadily increasing cause of morbidity and mortality
in the United States. It is the most common discharge diagnosis for adult patients and the
costliest major cause of inpatient admissions (Esposito et al., 2018). The Surviving Sepsis
Campaign was established in 2002 in an international effort to reduce mortality from sepsis.
They provided a standard-of-care approach to identifying and treating sepsis, the most recent
guideline having been released in 2016. The current basic principles involve early identification
of infection, fluid resuscitation, and broad-spectrum intravenous (IV) antibiotics until cultures
can assist with narrowing to a specific pathogen (Rhodes et al., 2017). Unfortunately, in the time
that it can take to identify the source of infection, many patients progress to septic shock, which
carries a mortality rate of up to 80% (Paoli et al., 2018).
The term sepsis is relatively new, and has formerly been interchangeable with conditions
such as bacteremia and systemic inflammatory response syndrome (SIRS). Sepsis is loosely
defined as a systemic infection that causes organ dysfunction. More specifically, a task force
formed by the Society for Critical Care Medicine (SCCM) and the European Society for
Intensive Care Medicine (ESICM) in 2016 defined sepsis as “life-threatening organ dysfunction
caused by a dysregulated host response to infection.” Septic shock, as defined by the Surviving
Sepsis Campaign is sepsis that results in hemodynamic instability, despite adequate fluid
resuscitation and use of vasopressor medications such as norepinephrine (Rhodes et al., 2017).
Part of the dysregulation of the immune response involves inflammation, oxidative stress, and
the body’s subsequent response. Given its antioxidant properties, the theoretical use of vitamin C
supplementation in sepsis is not necessarily new, but is being studied more intensely in recent
years, largely due to a promising 2016 retrospective study by Dr. Paul E. Marik of Norfolk,
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Virginia. His study involved a treatment bundle of ascorbic acid (vitamin C), thiamine (vitamin
B1), and hydrocortisone. Of note, hydrocortisone is recommended in the current Surviving
Sepsis protocol if the patient is displaying signs of septic shock (Rhodes et al., 2017). The
various mechanisms of action of ascorbic acid in the body will be discussed, as well as its
hypothesized mechanism of action in conditions of sepsis. Other treatments, such as thiamine
and hydrocortisone, along with their mechanisms of action, will also be explored.

Statement of the Problem
In the United States, nearly 1 million patients are admitted each year for sepsis. Many
sources suggest that the incidence is increasing. One study reports an increase of 8.7% per year
over the course of 20-years. More than half of all inpatient deaths are due to infection. In
addition to the lives lost, sepsis draws a large amount of money and resources. The average
inpatient length of stay for a patient with sepsis is 75% longer than for other illnesses, requiring
corresponding supplies and staffing. In 2013, only 3.6% of hospital stays were due to sepsis, but
this population utilized 13% of the cost of resources at approximately $24 billion. (Paoli, et al.,
2018) Oxidative stress on vasculature during acute sepsis can lead to hemodynamic instability,
increased inflammation, and death. Patients who progress from sepsis to septic shock have
mortality rates of approximately 30-50% (Carr, Shaw, Fowler, & Natarajan, 2015). Other
conditions with high morbidity and mortality rates such as cancer and heart disease, frequently
have new medications introduced. In 2017, the FDA approved sixteen new medications for
treatment of various cancers. Within the past 5 years, twenty new medications have been
approved for the treatment of cardiovascular diseases. Currently, the first new antibiotic in 30
years is under development. Aside from current antibiotics, there are no other mainstay
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medications in treatment of sepsis. In recent years, there have been many phase II and phase III
trials of potential treatments to improve mortality in sepsis, but none have proved to be
significant (Teng, Pourmand, & Mazer-Amirshahi, 2018). As previously discussed, the current
treatment guidelines are limited. Optimizing patient outcomes requires early identification of the
pathogen, which is not always realistic when considering variations in resources and levels of
care throughout the country. When sepsis progresses to septic shock and the patient begins to
exhibit hypotension, especially hypotension that does not respond to vasopressor medications,
clinicians are left with very few if any definitive treatment options. In the discussion of
Surviving Sepsis, Howell & Davis (2017) highlight hemodynamic therapy as a major area in
need of ongoing research. Ascorbic acid is a potent antioxidant, and serum levels of ascorbate, a
component of ascorbic acid, have shown to be depleted in the body in times of infection and
inflammation. Knowing this, it is reasonable to hypothesize that parenteral supplementation of
ascorbic acid could be beneficial in preventing this inflammatory damage.
Research Questions
What is the role of ascorbic acid in the human body and what theoretical mechanisms of
action does it have in a patient with sepsis?
In patients with sepsis, has administration of intravenous ascorbic acid been shown to
decrease mortality rates when compared to current standard of care?
At what dose might there be increased benefit from ascorbic acid supplementation, and is
that dose beyond the standard replacement from enteral or parenteral nutrition that is routinely
administered to critically ill patients?
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In treatment of sepsis, is intravenous ascorbic acid a cost effective treatment when
combined with the current regimen of intravenous fluid resuscitation and antibiotic therapy?
Methodology
For research and literature review, PubMed and CINAHL databases were used, along
with the NIH Clinical Trials website, to learn and gather information about the mechanism of
action of ascorbic acid in the body, its role in conditions of sepsis, the use of other products such
as thiamine and hydrocortisone in the treatment of sepsis, the safety of these treatments, and their
efficacy. The following search terms were utilized to locate the information: sepsis, vitamin C,
intravenous, treatment, ascorbic acid, scepticaemia, toxemia, cost, thiamine, hydrocortisone, and
septic shock. MeSH terms were used in the PubMed and CINAHL databases. Searches were
filtered to exclude studies and articles greater than 10 years old.
Literature Review
In reviewing the literature, there seems to be promising theoretical information to support
the use of this treatment. However, it remains controversial as there are very few completed
studies, and those that have been completed are not randomized, controlled studies, or have a
small number of subjects. There are currently seven studies in progress in the United States
regarding this treatment, with larger sample sizes as well as randomization, masking, and use of
placebos. Additionally, there are 11 international studies in progress.
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Mechanism of action of ascorbic acid in septic conditions.
Anecdotal advice regarding vitamin C may suggest that it has a role in the treatment or
prevention of illnesses such as the common cold. However, vitamin C (ascorbic acid) has been
proven to play many major roles in the normal function of the human body. The antioxidant
properties of ascorbic acid help to prevent oxidative stress from causing damage to cellular
proteins. It also aids in the creation and function of similarly-acting components. It helps to
produce catecholamines, cortisol, and vasopressin (Moscowitz et al., 2018). It is a vital part of
growth and repair of tissues due to its role in collagen formation, which is utilized throughout the
body in many areas, including tendons, ligaments, and vasculature. A 1942 issue of the New
England Journal of Medicine suggested that hypovitaminosis of vitamin C increased wound
healing time (Bartlett, Jones, & Ryan, 1942).
A 2017 study by Carr et al., discusses the effect of vitamin C in the body as it relates to
inflammation from sepsis. As we know, one of the roles of vitamin C is to work as an antioxidant
in the body. When the body is under stress, such as from trauma or infection, inflammation is
increased globally. Antioxidants help prevent damage from inflammatory states, and the authors
hypothesize that due to the increased metabolic demand of sepsis, serum vitamin C levels are
unable to be maintained at a level adequate to perform this task. Our bodies do not synthesize
ascorbic acid (vitamin C), and due to this lack of internal production, the body relies on dietary
intake to maintain appropriate levels of ascorbic acid in the body. Ascorbic acid has a vital role
in maintaining the normal physiologic function and structure of tissues in the body by preventing
oxidation of proteins and lipids. There has also been evidence to suggest that ascorbic acid plays
a role in DNA transcription. One of its cofactor functions that is particularly pertinent to patients
with critical illness or injury is that of synthesis of vasopressin and norepinephrine. Studies have
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shown that patients who are critically ill often also have corresponding ascorbic acid deficiency.
This deficiency has also been found to correlate with failure of multiple organ systems.
While hospitalized patients in septic shock often receive parenteral nutrition that includes
the recommended daily allowance of vitamin C (60mg), the thought is that due to the increased
use and protective benefit of vitamin C, that increasing the amount administered to these patients
would be a logical step in trying to counter this deficiency. When evaluating critically-ill patients
who were being given vitamin C as part of IV nutrition or tube feedings, and using the values of
vitamin C contained in those products, the resulting serum levels were estimated and then
measured. The assumption was that hypovitaminosis could be corrected by enteral or parenteral
supplementation that included vitamin C. However, the actual measured serum vitamin C levels
were approximately 33% of what they had been predicted to be following administration of these
nutritional replacement products. One hypothesis considered that when using enteral
supplementation in patients with critical illness, there may be some disruption in absorption that
would account for the difference in presumed serum levels versus actual. However, patients
receiving parenteral nutrition which would bypass the GI system entirely, also displayed this
persistent hypovitaminosis. Another potential cause of hypovitaminosis despite enteral/parenteral
nutrition that was considered is hemodilution, which can skew many different laboratory values.
This is especially possible in critically-ill patients, as they are often receiving high volumes of
fluid resuscitation as part of sepsis protocols. In this particular study, dilution was evaluated by
looking at hematocrit, which showed that dilution could account for about 25% of the difference
between predicted and actual serum values. Renal dialysis can also decrease serum vitamin C
levels by as much as 50%, and although there were five patients in this study who were
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undergoing dialysis, there did not appear to be a dialysis-specific correlation, as the
hypovitaminosis was still present in patients not undergoing dialysis.
In this study, the goal was not to evaluate the treatment of sepsis, but the relationship between
serum vitamin C levels and the severity of inflammation as measured by C-reactive protein
(CRP), an inflammatory marker often used to trend a patient’s response to treatment. Along with
following the CRP labs, the researchers also followed several mortality-predictor tools to
objectively evaluate and compare clinical status of the patients. These included the patient’s
Acute Physiology and Chronic Health Evaluation II score (APACHE II), Simplified Acute
Physiology II score (SAPS II), and Sequential Organ Failure Assessment (SOFA) scores. The
APACHE II evaluation tool uses information such as patient age, vital signs, lab values
(electrolytes, WBC, hematocrit), FiO2 if intubated, presence or absence of renal failure, and
history of severe organ failure or immunocompromise to estimate the likelihood of mortality of
an adult inpatient in critical/intensive care. The SAPS II is similar, and used for prognosis in the
same demographic, with some exclusions of criteria used by the APACHE II and the addition of
urine output and bilirubin. The SOFA scoring system also takes platelet count into consideration.
There is also a variation of the SOFA called the quick Sequential Organ Failure Assessment
(qSOFA) that evaluates the patient’s Glascow Coma Scale (GCS) score, respiratory rate, and
systolic blood pressure. The goal of the qSOFA is to identify patients who are not yet in a
critical care unit and evaluate their risk for mortality. This is then used to make decisions
regarding treatment and plan of care. The study divided subjects into those with septic shock
(n=24) and those without (n=17). While the study provides a good baseline for later evaluation
of whether supplementing sepsis patients with additional vitamin C is beneficial, the study was
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observational, used a relatively small number of subjects, and was short in duration at only 4
days.
Research on ascorbic acid use in patients with sepsis has focused largely on the
antioxidant and anti-inflammatory effects. One aspect of sepsis that leads to high mortality is
decreased cardiac output and accompanying hypoperfusion related to intractable hypotension.
This is often despite fluid resuscitation combined with use of vasoconstrictors such as
norepinephrine and vasopressin. Carr et al., (2015) suggests that in addition to antioxidant and
anti-inflammatory effects, vitamin C could provide support for endogenous vasopressin, thus
decreasing the need for synthetic administration. This study used CRP, procalcitonin, and SOFA
scores to trend patient condition and response to treatment with ascorbic acid, as well as
thrombomodulin levels to assess the status of vascular endothelium. This randomized, controlled
study showed a decrease in CRP, procalcitonin, and SOFA scores, as well as a reduction of
thrombomodulin. This decrease of thrombomodulin suggests that the ascorbic acid may be
relieving some injury to the vascular endothelium. This study, again, used a small number of
subjects at only 24. Although trending the CRP and procalcitonin is useful for following patient
response, the focus of the study was vascular endothelial damage in sepsis, so focusing more
heavily on the thrombomodulin would have been most appropriate.
Patients with sepsis or septic shock are not only harmed by the bacteria themselves, but
also by the endotoxin release caused by treatment. These factors plus side effects of the immune
response itself can lead to widespread microvascular dysfunction, including hypoperfusion and
increased capillary permeability. The result is a patient that is not able to respond to fluid
resuscitation and vasoconstrictors. This type of dysfunction is a major predictive factor in
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mortality of septic patients. Wilson (2009) discusses the fact that capillary hypoperfusion can be
alleviated by parenteral ascorbic acid, and that this positive effect lasts for several hours after
serum levels have once again decreased. The author also briefly addresses the possibility that
ascorbic acid could have some benefit in attenuating microvascular thrombi that can occur in
severe sepsis. This author states that the safety of parenteral ascorbic acid requires further study,
however the literature reviewed has revealed no major adverse events. High doses of ascorbic
acid can theoretically cause oxalate stone formation, especially in patients who are predisposed
to renal stones, so this is a consideration. Zabet, Mohammadi, Ramezani, & Khalili (2016)
compared placebo to ascorbic acid in a double-blind, randomized clinical trial with 28 patients.
The patient condition was measured using the definition of sepsis provided by the Surviving
Sepsis Campaign. These factors included fever, tachycardia, leukocytosis or leukopenia, organ
dysfunction as evidenced by respiratory compromise, decreased urine output despite
interventions, increased platelet count, and acute coagulopathy. The Surviving Sepsis treatment
recommendations were also followed in addition to the administration of either ascorbic acid or
placebo. These treatments included fluid resuscitation, antibiotic administration appropriate for
each patient, stress ulcer prophylaxis, and deep vein thrombosis (DVT) prophylaxis. To track
patient condition and response to treatment, their APACHE II and SOFA scores were used, as
well as vital signs, fluid intake/output, renal function, and serum electrolytes. The total amount
(P= 0.003) of synthetic vasopressin administered for hemodynamic support and the duration
needed (P= 0.007) was significantly less in the group of patients who received ascorbic acid than
in the placebo group. None of the patients who received ascorbic acid experienced any related
adverse events. The survival rate of the control group over the 28 days following the study was
greater than that of the placebo group (P= 0.009). The author discusses more extensively than
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others the ascorbic acid dosing that may be most effective for patients with sepsis. However, he
admits that both the dosing and ideal place on the treatment timeline still need further research.
The study had a small number of subjects, as well as a short duration. This study also did not
measure each patient’s baseline serum ascorbic acid level prior to initiating treatment.
Safety and efficacy of intravenous ascorbic acid in the treatment of sepsis.
One of the concerns about implementing ascorbic acid as a treatment for sepsis is that of
safety considerations. In this randomized, double-blind, placebo-controlled trial, the goal was to
determine the safety of ascorbic acid when administered parenterally to patients with severe
sepsis. The secondary goal of the trial was to evaluate the impact of ascorbic acid on organ
failure in these patients. The selected patients were ones who were identified as suffering from
severe sepsis, as traditionally defined. For reference, the recommended daily allowance (RDA)
for vitamin C is 60mg. The groups created were those of placebo, low-dose ascorbic acid, and
high-dose ascorbic acid. Low dose was defined as 50mg/kg/24 hours and high dose as
200mg/kg/24 hours. Patient SOFA scores were calculated initially and then serially at 24, 48, 72,
and 96 hours. To evaluate for adverse effects, vital signs were closely monitored during
administration and for 45 minutes after. Patients were monitored for hypotension, tachycardia,
hypernatremia, and nausea/vomiting. Of a total of 26 patients, 8 were in the placebo group, 8 in
the low-dose ascorbic acid group, and the remaining 10 in the high-dose ascorbic acid group. No
patients were removed from the study due to adverse events. Once patient appeared to have a
ventricular arrythmia during administration, at which point it was stopped. This was later
evaluated by a cardiologist and determined to be artifact. Patient serum ascorbic acid levels were
evaluated prior to onset of treatment and were all below normal limits. Once again, larger sample
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sizes would provide stronger evidence, but the results of this trial still appear to be promising.
The author cites the need for a larger, phase II proof-of-concept trial (Fowler et al., 2014).
Teng et al., (2018) discusses the effects of sepsis on the body, including widespread
inflammation and multi-organ dysfunction leading to significant morbidity and mortality rates.
The current treatment recommended by the Surviving Sepsis campaign does not include a
component to address the inflammation and effects of oxidative stress. There have been other
treatments studied for this purpose, such as anti-tumor necrosis factor (TNF) receptor antibodies,
recombinant human activated protein C, and anti-LPS HA-1A antibodies, but none of these
showed a long-term improvement in patient outcomes. Ascorbic acid has many actions in the
body, including combatting oxidative changes, vasopressor synthesis, and assistance with
immune function. All of these features lend themselves to the theoretic possibility of a successful
adjunct treatment of sepsis. At this time, our evaluation of this treatment remains limited to a
small number of studies, and of those studies, most had a sample size of less than 50 subjects.
Furthermore, the studies reviewed used differences in dosing and some used other components in
combination with ascorbic acid. This makes evaluation of ascorbic acid alone somewhat difficult
with current data. Li (2018) attempts to support the limited evidence by doing a meta-analysis of
the several small studies that have been published regarding the use of ascorbic acid in the
treatment of sepsis. The similarities between the three studies compared were mortality rates of
patients who were treated with ascorbic acid versus those who were not, ICU length of stay, and
duration of vasopressor use. The author found that although the specific parameters of each study
were different, these similarities allowed him to confirm a positive relationship between
treatment with vitamin C in sepsis and improved patient outcomes. Also referenced is the low
cost and relatively wide availability of ascorbic acid. It is helpful to have a comparison between
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dissimilar studies to strengthen evidence that there is need for further research into this
treatment. However, large clinical trials are still the mainstay needed before widespread
implementation can take place.
While studies with administration of high-dose IV ascorbic acid have shown no adverse
effects, there are a number of theoretical effects that should be noted. Excess ascorbic acid can
cause gastrointestinal upset such as pain and/or bloating, may falsely elevate point-of-care blood
glucose evaluation in certain types of testing equipment, and in patients with G6PD deficiency
hemolysis may occur. Regarding efficacy, in the study discussed that compared septic patients
given high-dose IV ascorbic acid (200mg/kg), low-dose ascorbic acid (50mg/kg) or placebo, the
patients who received the high-dose ascorbic acid saw a faster rate of improvement in terms of
decreasing need for exogenous vasopressors and decreased need for mechanical ventilation.
Marik (2017) has been credited with bringing this treatment into the public eye most
recently. His study evaluated outcomes of 94 patients being treated for sepsis. The primary
outcome evaluated was in-hospital survival. He used a combination of ascorbic acid, thiamine,
and hydrocortisone to treat 47 patients and then retrospectively matched them to previous
patients with similar conditions who had been treated using only traditional standard of care for
sepsis. The results appear to be dramatic. The treatment group saw only 4 fatalities, and no
patients developed progressive organ failure. Of the 4 fatalities, those deaths were deemed
inevitable due to underlying, preexisting disease. Marik’s study, while it brought much publicity
to this potential treatment, utilizes a combination treatment, is retrospective, observational, and
has a small sample size. Marik himself notes that the time difference in the treatment and control
groups may also be a limitation. Multiple studies have revealed that vitamin C hypovitaminosis
correlates with the severity of illness and multiple organ system involvement and that patients
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critically ill due to sepsis are more likely to display decreased levels of vitamin C than patients
who are ill due to non-sepsis causes. Carr et al., (2017) found that C-reactive protein levels were
shown to be inversely related to that of serum vitamin C levels, and supplementation of vitamin
C appeared to cause C-reactive protein levels to decrease.
Discussion of other treatment components
Several studies are focusing on the theoretical use of ascorbic acid in sepsis. The Marik bundle
includes thiamine and hydrocortisone, the latter of which is already included in current best
practices for sepsis patients who meet the criteria. The addition of thiamine has several
hypothetical reasons for being utilized in sepsis. It is not uncommon to find thiamine deficiency
in a patient with sepsis (Marik, 2018). It is also not uncommon for these patients to have elevated
lactic acid, which indicates poor organ and tissue perfusion, and is highly suggestive of a poor
prognosis. Thiamine plays a role in the Krebs cycle, and without sufficient levels, the body must
utilize its anaerobic pathway, the byproducts of which elevate lactate levels in the body. This
would suggest that maintaining sufficient levels of thiamine during sepsis could assist in the
maintenance of a lactate level within normal limits. There also is literature to suggest significant
improvement of patient condition after thiamine administration in deficient septic patients (Leite
& de Lima, 2016).
As previously discussed, the Surviving Sepsis recommendation for use of hydrocortisone
in sepsis is that it be administered only in patients who do not hemodynamically respond to
adequate, weight-based fluid resuscitation and vasopressor medications such as norepinephrine
and vasopressin.
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Stated time and again, the hallmark of sepsis is unchecked inflammation that can lead to
multiple system organ dysfunction. For over 50 years, steroids have been used in the treatment of
septic shock because of their known anti-inflammatory properties (Annane, 2011).
Glucocorticoids have been shown to quickly decrease platelet aggregation, reduce cell adhesions,
and up-regulate endogenous anti-inflammatory factors. Through induction of sodium retention,
corticosteroids help to correct the hypovolemic state often seen in sepsis while simultaneously
increasing vascular resistance. Corticosteroids given to septic shock patients have been shown to
decrease the time that patients require vasopressor medications and increase their chance of
discontinuing this support by 35% (Annane, 2011). Data has shown that glucocorticoids inhibit
tumor necrosis factor from being released from vasculature and corticosteroids have shown to
have a positive effect on the permeability of the glomerular endothelium, which assists in
returning the body to normal sodium and water regulation. Patients who are given corticosteroids
in septic shock were also discharged from critical care units on average 4.5 days sooner than
patients who were not (Annane, 2011).
The role of combining corticosteroids with ascorbic acid for treatment of sepsis is that of
their theoretic synergistic effects. Ascorbic acid in the body helps to restore glucocorticoid
receptor function, allowing the administered steroids to bind. Exogenous steroid administration
helps to increase expression of sodium-vitamin-C-transport (SVCT2), which is downregulated
during the inflammatory response. When combined, ascorbic acid and corticosteroids have been
shown to increase the effect of tissue barrier protection beyond what either can do independently
(Moskowitz et al., 2018).
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Although there is some plausible concern regarding the use of steroids in patients with infection
due to their immunosuppressive nature (Chantham, 2018), recent analyses did not find any
consistent evidence to suggest that steroids given to septic patients creates an increased risk for
superinfections (Annane, 2011).
Cost considerations
Mayr, Yende, & Angus (2014) list sepsis as the most common cause of inpatient deaths
in non-cardiac critical care units in the United States, with the septic shock mortality rate
approaching 50%. In 2001, the Consensus Conference by the Society of Critical Care
Medicine/European Society of Intensive Care Medicine/American College of Chest
Physicians/American Thoracic Society/Surgical Infection Society suggested a more explicit
definition of septic shock to include systolic blood pressure readings of <90mmHg or a mean
arterial pressure (MAP) of <70mmHg. A consistent definition could help to better track
morbidity and mortality.
Epidemiology of sepsis is difficult to assess internationally due to differences in
documentation, access to care, and cultural approach to illness. Another limitation when
assessing sepsis statistics is that of comorbid factors in any population. A patient with comorbid
conditions may be more likely to suffer from acute sepsis and patients who survive acute sepsis
may have subsequent chronic illnesses related to the infection and its effects. Most studies
measure mortality rates using 28 or 90-day survival with no further follow up, but even patients
who survive beyond the 90-day point are 3x more likely to have functional and/or cognitive
limitations following hospitalization. Moskowitz et al., (2018) also discusses the frequent issue
of post-discharge residual organ dysfunction. Also discussed is the highest-risk patient
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population in the United States in regard to sepsis, which is older, black males with preexisting
health conditions and the need to target this population for prevention and education.
Esposito et al., (2018) discusses costs related to early intervention of possible sepsis.
Much of this early treatment is based on reimbursement and quality measures, and may be
altering the data, which currently shows that sepsis mortality is decreasing, but that incidence is
increasing. One non-treatment related explanation for this is that more patients are being
incorrectly diagnosed with sepsis due to hospital policies, reimbursement, and quality measures,
who likely would not have succumbed to sepsis and thus appear in the numbers as a successful
treatment. A diagnosis of sepsis initiates a costly treatment bundle, which is worth the cost if
successful and appropriate. The author compiled 3 years of retrospective data that showed no
change in mortality, but a significant increase in cost and resources used, including antibiotics,
blood cultures, and lactate levels. Although Esposito et al., (2018) does not address the use of
ascorbic acid as a treatment in sepsis and is focusing on the costs of over treatment, it is relevant
to the discussion of cost, as true sepsis is very costly to patients and the healthcare system as a
whole.
Arefian et al., (2017) cites that out of the 19.4 million cases worldwide of severe sepsis
annually, the mean hospital cost of sepsis per stay is approximately $32,421 and mean ICU cost
is approximately $4,651 per day, with costs increasing exponentially with severity of illness.
However, the estimated costs have many variables, such as patient demographic, type or location
of infection, and preexisting comorbidities. These factors make it difficult to make accurate
comparisons over time. The data analyzed by Arefian et al., (2017) encompassed a 10-year
period and included 37 studies and/or articles.
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Cost analysis comparing protocol-driven care of sepsis patients versus a control group showed a
57% mortality rate in the control group compared to 38% in the managed care group (P = .002).
This reveals an 18% absolute and 31.8% relative risk reduction. The total ICU cost in the control
group was $138,237 versus $85,484 in the managed care group. Cost and immediate mortality
aside, the analysis also revealed an increased life expectancy of 3.2 years post discharge in the
managed care group. Not discussed was the functional capacity of these patients post discharge
(Assuncao et al., 2014).
In discussing sepsis incidence and trends, Rhee (year) suggests that although many
articles have stated that rates of sepsis are increasing while sepsis mortality is decreasing, this
may not be the case. In this analysis, the incidence of sepsis appeared to remain relatively stable,
with a decrease in inpatient mortality. Overall mortality did not appear to have decreased. Once
again, this data may be skewed by recent increased awareness that can lead to a greater number
of diagnoses, change in diagnosis criteria, and differences in documentation and coding.

Delaying implementation of treatment.
This review of information attempts to analyze and quantify the risks and benefits of
implementing a new sepsis protocol with the addition of ascorbic acid, as well as thiamine and
hydrocortisone. These treatments together make up what the author refers to as the Marik sepsis
bundle, referencing Dr. Paul Marik whose treatment plan has recently brought more awareness to
ascorbic acid as a tool to combat sepsis. Along with the risks of early implementation prior to
large, randomized studies being completed, the risks of not implementing this treatment are also
discussed. One of the concerns regarding early implementation is that implementing new
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treatments based on limited information and small, observational studies could set a dangerous
precedent. If it was implemented and then later found to be ineffective, large amounts of time
and money spent on training would be wasted. However, if it is ultimately found to be as
effective as it appears to be, or even somewhat less, many lives could be saved in the amount of
time that it takes to complete a large-scale clinical trial and compile the results. Aside from
mortality, there are also cost considerations in regard to hospitalization and long-term
complications post sepsis. Due to the fact that the treatment components themselves are
relatively low cost, and the fact that thiamine and hydrocortisone, as well as ascorbic acid in
smaller doses, are already often administered to critically-ill patients, and the lack of evidence
demonstrating serious adverse effects from high-dose ascorbic acid, it seems reasonable in this
case to consider early implementation of this adjunct sepsis treatment. The major flaw in this
discussion is that since this treatment is not being widely used, the costs and patient outcomes
were theoretical and based on an observational study with a small sample size. More specific
cost estimates for the treatment as well as for training of staff could be useful to aid in decisionmaking (Blythe, Cook, & Graves, 2018).

PARENTERAL ASCORBIC ACID FOR SEPSIS

23

Discussion
Due to the large incidence and society cost of sepsis and its sequelae, this has long been a
major area of research. Several novel sepsis treatments have appeared promising and failed to
produce meaningful results at the clinical trial level. Although the seemingly-dramatic outcomes
have been met with skepticism by many, the current literature suggests that ascorbic acid may be
the most promising new treatment for sepsis that clinicians have seen in a very long time. Its
mechanism of action in the body serves many roles that are not only vital to the healthy
individual, but physiologically suffering in cases of sepsis. As previously mentioned, there are
several currently active clinical trials studying the use of intravenous ascorbic acid in treating
patients with sepsis. Within the next few years, antioxidant therapy may become a viable
treatment adjunct for patients with severe sepsis. At a minimum, if it shows enough benefit in
early trials, the relatively low cost as well as lack of risk of adverse effects may allow it to be
implemented as part of a sepsis protocol. In addition to larger sample sizes and blind, placebocontrolled trials, a specific dosing recommendation would need to be established, as well as at
what point ascorbic acid would be administered during the timeline of the sepsis protocol. It
would also be helpful to determine whether the addition of thiamine in the Marik bundle
produces the best results, or if ascorbic acid alone is sufficient to reduce mortality.
What is the role of ascorbic acid in the human body and what theoretical mechanisms of
action does it have in a patient with sepsis?
Ascorbic acid assists with endogenous vasopressin production, reduces damage from
oxidative stress, and decreases inflammation. Patients with sepsis often require exogenous
vasopressors and much damage is caused by the body’s inflammatory response. The physiologic
role of ascorbic acid in the body corresponds to several deficient areas during systemic infection.
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In patients with sepsis, has administration of intravenous ascorbic acid been shown
to decrease mortality rates when compared to current standard of care?
The studies discussed show a statistically significant reduction in sepsis-related mortality.
However, the studies have small sample sizes, are retrospective, observational, or have other
limitations previously discussed. At this time, although the current results seem to show a
positive correlation, the evidence is not strong enough to definitively say whether IV ascorbic
acid will consistently decrease mortality rates (Langlois & Lamontagne, 2018). Long-term
studies are also needed to not only evaluate mortality at the usual 28 or 90-day mark, but to
evaluate return to previous functional capacity, independence, and quality of life.
At what dose might there be increased benefit from ascorbic acid supplementation,
and is that dose beyond the standard replacement from enteral or parenteral nutrition that
is routinely administered to critically ill patients?
There has been little evidence to suggest that low-dose ascorbic acid supplementation is
effective in raising serum levels or improving outcomes (Langlois & Lamontagne, 2018). The
results that have been shown have been either at unspecified doses or at high doses such as
200mg/kg over 24 hours. This is far beyond that which is included in standard nutrition
replacement, whether IV or enteric.
In treatment of sepsis, is intravenous ascorbic acid a cost effective treatment when
combined with the current regimen of intravenous fluid resuscitation and antibiotic
therapy?
At this time we cannot accurately infer any cost savings gained from the use of ascorbic
acid. This is because the addition of ascorbic acid would not replace the current standard-of-care
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medications and fluids used in sepsis, such as antibiotics, crystalloids, and vasopressor
medications. However, intravenous ascorbic acid itself is relatively low cost, and if it is proven
to improve outcomes, this will likely produce a cost savings by way of reduced length of hospital
stay. This translates to reduction in cost of resources, as well as potential healthcare cost savings
by reducing the amount of follow-up such as transitional care, skilled nursing or swing-bed
facilities. If the current studies in progress find significant benefit from the use of ascorbic acid
for sepsis, the cost effects will then be able to be determined.

Application to Clinical Practice
As stated, there are several trials currently in various stages. There are several areas that
will need to be addressed before widespread implementation can take place. While this research
currently applies to critical care as opposed to primary care, significant benefit from use of highdose ascorbic acid in infectious disease could translate to research its use in less severe illness.
As more research becomes available, the use of parenteral ascorbic acid could be a life-saving
and cost-effective treatment option for patients with severe sepsis.
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